Oral administration of interferon-α2b-transformed Bifidobacterium longum protects BALB/c mice against coxsackievirus B3-induced myocarditis

Virology Journal

Weiseng Zeng²  Qiwen Deng¹  Zhongming Zeng¹  Lili Deng¹  Jin Yang¹  Fan Zhang¹  Yuanjian Huang²  Chongwen Shao²  Zhen Huang¹  Zhijian Yu¹ 

[1] Department of Infectious Diseases, the Affiliated Shenzhen Nanshan Hospital of Guangdong Medical College, No 89, Taoyuan Road, Nanshan district, 518052 Shenzhen, China;Department of Cell Biology, Southern Medical University, No 1023, Satai Raod, Baiyun district, 510515 Guangzhou, China

关键词: Oral administration;    Myocarditis;    Interferon;    Enterovirus;    Coxsackievirus B;    Bifidobacterium;   

Others  :  1155576
DOI  :  10.1186/1743-422X-8-525

 received in 2011-07-22, accepted in 2011-12-08,  发布年份 2011

【 摘 要 】

Multiple reports have claimed that low-dose orally administered interferon (IFN)-α is beneficial in the treatment of many infectious diseases and provides a viable alternative to high-dose intramuscular treatment. However, research is needed on how to express IFN stably in the gut. Bifidobacterium may be a suitable carrier for human gene expression and secretion in the intestinal tract for the treatment of gastrointestinal diseases. We reported previously that Bifidobacterium longum can be used as a novel oral delivery of IFN-α. IFN-transformed B. longum can exert an immunostimulatory role in mice; however the answer to whether this recombinant B. longum can be used to treat virus infection still remains elusive. Here, we investigated the efficacy of IFN-transformed B. longum administered orally on coxsackie virus B3 (CVB3)-induced myocarditis in BALB/c mice. Our data indicated that oral administration of IFN-transformed B. longum for 2 weeks after virus infection reduced significantly the severity of virus-induced myocarditis, markedly down regulated virus titers in the heart, and induced a T helper 1 cell pattern in the spleen and heart compared with controls. Oral administration of the IFN-transformed B. longum, therefore, may play a potential role in the treatment of CVB3-induced myocarditis.

【 授权许可】

   
2011 Yu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Katabira ET, Sewankambo NK, Mugerwa RD, Belsey EM, Mubiru FX, Othieno C, Kataaha P, Karam M, Youle M, Perriens JH, Lange JM: Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial. Sex Transm Infect 1998, 74(4):265-270.
• [2]Cummins J, Beilharz M, Krakowka S: Oral use of interferon. J Interferon Cytokine Res 1999, 19:853-857.
• [3]Hutchinson VA, Mok WL, Angenend JL, Cummins JM, Richards AB: Chronic major aphthous stomatitis: oral treatment with low-dose alpha-interferon. Mol Biother 1990, 2(4):217-220.
• [4]Lecciones JA, Abejar NJ, Dimaano EE, Bartolome R, Cinco S, Mariano N, Yerro ME, Cobar S, Fuggan B: A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-α-n1 (Ins) in pediatric patients with measles. J Interferon Cytokine Res 1998, 18:647-652.
• [5]Kim Y, Thapa M, Hua DH, Chang KO: Biodegradable nanogels for oral delivery of interferon for norovirus infection. Antiviral Res 2011, 89(2):165-173.
• [6]Dec M, Puchalski A: Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases. Pol J Vet Sci 2008, 11:175-186.
• [7]Hu B, Kou L, Li C, Zhu LP, Fan YR, Wu ZW, Wang JJ, Xu GX: Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. Cancer Gene Ther 2009, 16:655-663.
• [8]Reyes Escogido ML, De León Rodríguez A, Barba de la Rosa AP: A novel binary expression vector for production of human IL-10 in Escherichia coli and Bifidobacterium longum. Biotechnol Lett 2007, 29:1249-1253.
• [9]Shkoporov AN, Efimov BA, Khokhlova EV, Kafarskaia LI, Smeianov VV: Production of human basic fibroblast growth factor (FGF-2) in Bifidobacterium breve using a series of novel expression/secretion vectors. Biotechnol Lett 2008, 30:1983-1988.
• [10]Tang W, He Y, Zhou S, Ma Y, Liu G: A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer. J Exp Clin Cancer Res 2009, 28:155. BioMed Central Full Text
• [11]Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y, Taniguchi S: Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 2001, 66:165-170.
• [12]Deng Q, Zeng W, Yu Z: Signal peptide of Arabinosidase enhances secretion of interferon-alpha2b protein by Bifidobacterium longum. Arch Microbiol 2009, 191:681-686.
• [13]Yu Z, Zeng Z, Huang Z, Lian J, Yang J, Deng Q, Zeng W: Increased mRNA expression of interferon-induced Mx1 and immunomodulation following oral administration of IFN-α2b-transformed B. longum to mice. Arch Microbiol 2010, 192:633-638.
• [14]Heim A, Grumbach I, Pring-Akerblom P, Stille-Siegener M, Muller G, Kandolf R, Figulla HR: Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon-alpha. Antivir Res 1997, 34:101-111.
• [15]Kandolf R, Canu A, Hofschneider PH: Coxsackie B3 virus can replicate in cultured human fetal heart cells and is inhibited by interferon. J Mol Cell Cardiol 1985, 17:167-181.
• [16]Okada I, Matsumori A, Matoba Y, Tominaga M, Yamada T, Kawai C: Combination treatment with ribavirin and interferon for coxsackievirus B3 replication. J Lab Clin Med 1992, 120:569-573.
• [17]Padalko E, Nuyens D, De Palma A, Verbeken E, Aerts JL, De Clercq E, Carmeliet P, Neyts J: The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother 2004, 48(1):267-274.
• [18]Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN: Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 2004, 110:3540-3543.
• [19]Wang YX, da Cunha V, Vincelette J, White K, Velichko S, Xu YF, Gross C, Fitch RM, Halks-Miller M, Larsen BR: Antiviral and myocyte protective effects of murine interferon-beta and -alpha2 in coxsackievirus B3-induced myocarditis and epicarditis in BALB/c mice. Am J Physiol Heart Circ Physiol 2007, 293:H69-H76.
• [20]Wang YF, Wang XY, Ren Z, Qian CW, Li YC, Kaio K, Wang QD, Zhang Y, Zheng LY, Jiang JH, Yang CR, Liu Q, Zhang YJ: Phyllaemblicin B inhibits coxsackie virus B3 induced apoptosis and myocarditis. Antiviral Res 2009, 84(2):150-158.
• [21]Yuan J, Yu M, Lin QW, Cao AL, Yu X, Dong JH, Wang JP, Zhang JH, Wang M, Guo HP, Cheng X, Liao YH: Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol 2010, 185(7):4004-4010.
• [22]Alignani D, Maletto B, Liscovsky M, Rópolo A, Morón G, Pistoresi-Palencia MC: Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J Leukocyte Biol 2005, 77:898-905.
• [23]Bollati-Fogolín M, Müller W: Virus free, cell-based assay for the quantification of murine type I interferons. J Immunol Methods 2005, 306:169-175.
• [24]Petry H, Cashion L, Szymanski P, Ast O, Orme A, Gross C, Bauzon M, Brooks A, Schaefer C, Gibson H, Qian H, Rubanyi GM, Harkins RN: Mx1 and IP-10: biomarkers to measure IFNbeta activity in mice following gene-based delivery. J Interferon Cytokine Res 2006, 26:699-705.
• [25]Dennert R, Crijns HJ, Heymans S: Acute viral myocarditis. Eur Heart J 2008, 29:2073-2082.
• [26]David RL: CRC Handbook of Chemistry and Physics. 88th edition. Boca Raton: CRC Press; 2007:110.
• [27]Yao J, Wang JY, Lai MG, Li YX, Zhu HM, Shi RY, Mo J, Xun AY, Jia CH, Feng JL, Wang LS, Zeng WS, Liu L: Treatment of mice with dextran sulfate sodium-induced colitis with human interleukin 10 secreted by transformed Bifidobacterium longum. Mol Pharm 2011, 8(2):488-497.